retatrutide phase 2 nejm 2023 weight loss percent 48 weeks Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a trial VisualAbstract: Retatrutide reduces body weight

These drugs are called GLP-1 receptor agonists because they can bind to GLP-1 receptors and produce the same effects as the naturally occurring GLP-1 hormone

One, gastric sleeve surgery, removes around 80% of the stomach, causing the patient to feel fuller sooner and reducing hormonal signals that impact appetite and metabolism

Improved Visceral Fat and Cardiometabolic Markers Retatrutide is likely to have superior effects on: Triglyceride levels LDL particle size and ApoB Insulin resistance (HOMA-IR) In patients with obesity, reduction of visceral fat is more critical than just total weight

Endotoxin contamination is a direct consequence of manufacturing environments that do not meet pharmaceutical cleanroom standards

The winner will depend on Phase 3 data, tolerability, approval timing, label breadth, payer access, and real-world persistence

Mercedez Hernandez, MD, is an assistant professor at the CU Anschutz School of Medicine, Division of Family Medicine